Roche’s first-to-market Lunsumio (mosunetuzumab) is currently indicated as a third-line or later therapy for FL, while stablemate Columvi (glofitamab) can be used to treat DLBCL or large B-cell ...

and lymphoma therapy Lunsumio (mosunetuzumab). "For the current year we expect solid underlying growth in both divisions, which will largely compensate for the further significant drop in sales of ...

After hours: March 14 at 7:58:00 PM EDT Loading Chart for BIIB ...

After hours: March 14 at 7:58:00 p.m. EDT Loading Chart for BIIB ...

After hours: 14 March at 7:58:00 pm GMT-4 Loading Chart for BIIB ...

After hours: 13 March at 7:37:36 pm GMT-4 Loading Chart for BIIB ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...